| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA892: Mosunetuzumab for treating relapsed or refractory follicular lymphoma |
|
Medicine details |
|
| Medicine name | mosunetuzumab (Lunsumio®) |
| Formulation | intravenous injection |
| Reference number | 4690 |
| Indication | As monotherapy is indicated for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least two prior systemic therapies |
| Company | Roche Products Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 27/05/2022 |
| NICE guidance | TA892: Mosunetuzumab for treating relapsed or refractory follicular lymphoma |